The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
ApexOnco Front Page
Recent articles
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
New draft guidance could see the agency getting ever stricter.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Posters and mini-orals include another VEGF bispecific.
Interius, one of the most advanced players, will cost $350m.
